Suppr超能文献

Stat5a/b N 端截短可绕过 PIAS3 介导的前列腺癌细胞中 Stat5 的转录抑制。

N-terminal truncation of Stat5a/b circumvents PIAS3-mediated transcriptional inhibition of Stat5 in prostate cancer cells.

机构信息

Department of Cancer Biology, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA 19107, USA.

出版信息

Int J Biochem Cell Biol. 2010 Dec;42(12):2037-46. doi: 10.1016/j.biocel.2010.09.008. Epub 2010 Sep 18.

Abstract

Transcription factor Stat5a/b is critical for prostate cancer cell survival and for prostate xenograft tumor growth. In addition, the Stat5a/b signaling pathway may contribute to progression of organ-confined prostate cancer to castration-resistant and/or metastatic disease. Expression of nuclear Stat5a/b is clustered to high grade human prostate cancers, and nuclear Stat5a/b in primary prostate cancer predicts early disease recurrence after initial treatment. Here, we show by Western blotting and electromobility shift assay that Stat5a/b protein in human prostate cancer is N-terminally truncated. This short form of Stat5a/b is generated post-translationally in vivo in prostate cancer cells and is the predominant form of Stat5a/b that binds to DNA. We further demonstrate by mutagenesis and co-immunoprecipitations that the N-domain of Stat5a/b is required for binding to PIAS3, and that PIAS3 inhibits transcriptional activity of Stat5a/b in breast cancer cells but not in prostate cancer cells. Thus, the proteolytic cleavage of the N-terminus of Stat5a/b may be a mechanism by which Stat5 evades the transcriptional repression by PIAS3 in prostate cancer cells, and results in increased Stat5-driven gene expression and prostate cancer progression.

摘要

转录因子 Stat5a/b 对前列腺癌细胞的存活和前列腺异种移植肿瘤的生长至关重要。此外,Stat5a/b 信号通路可能导致局限性前列腺癌向去势抵抗和/或转移性疾病的进展。核 Stat5a/b 的表达与高级别人类前列腺癌聚集在一起,原发性前列腺癌中的核 Stat5a/b 可预测初始治疗后早期疾病复发。在这里,我们通过 Western blot 和电泳迁移率变动分析显示,人前列腺癌中的 Stat5a/b 蛋白 N 端截短。这种 Stat5a/b 的短形式在体内前列腺癌细胞中转录后产生,是与 DNA 结合的 Stat5a/b 的主要形式。我们进一步通过诱变和共免疫沉淀证明,Stat5a/b 的 N 结构域是与 PIAS3 结合所必需的,并且 PIAS3 抑制乳腺癌细胞中 Stat5a/b 的转录活性,但不抑制前列腺癌细胞中的转录活性。因此,Stat5a/b 的 N 端的蛋白水解切割可能是 Stat5 逃避前列腺癌细胞中 PIAS3 的转录抑制的机制,导致 Stat5 驱动的基因表达增加和前列腺癌进展。

相似文献

1
N-terminal truncation of Stat5a/b circumvents PIAS3-mediated transcriptional inhibition of Stat5 in prostate cancer cells.
Int J Biochem Cell Biol. 2010 Dec;42(12):2037-46. doi: 10.1016/j.biocel.2010.09.008. Epub 2010 Sep 18.
5
STAT5A/B gene locus undergoes amplification during human prostate cancer progression.
Am J Pathol. 2013 Jun;182(6):2264-75. doi: 10.1016/j.ajpath.2013.02.044. Epub 2013 May 7.
6
Expression of STAT5, COX-2 and PIAS3 in correlation with NSCLC histhopathological features.
PLoS One. 2014 Aug 19;9(8):e104265. doi: 10.1371/journal.pone.0104265. eCollection 2014.
7
STAT5A/B Blockade Sensitizes Prostate Cancer to Radiation through Inhibition of RAD51 and DNA Repair.
Clin Cancer Res. 2018 Apr 15;24(8):1917-1931. doi: 10.1158/1078-0432.CCR-17-2768. Epub 2018 Feb 26.
8
Signal transducer and activator of transcription 5a/b: biomarker and therapeutic target in prostate and breast cancer.
Int J Biochem Cell Biol. 2011 Oct;43(10):1417-21. doi: 10.1016/j.biocel.2011.06.007. Epub 2011 Jun 17.
9
Inhibition of Stat5a/b Enhances Proteasomal Degradation of Androgen Receptor Liganded by Antiandrogens in Prostate Cancer.
Mol Cancer Ther. 2015 Mar;14(3):713-26. doi: 10.1158/1535-7163.MCT-14-0819. Epub 2014 Dec 31.
10
Transcription factor Stat5 synergizes with androgen receptor in prostate cancer cells.
Cancer Res. 2008 Jan 1;68(1):236-48. doi: 10.1158/0008-5472.CAN-07-2972.

引用本文的文献

2
Association of Selected STAT Inhibitors with Prolactin-Induced Protein (PIP) in Breast Cancer.
Int J Mol Sci. 2025 Feb 7;26(4):1416. doi: 10.3390/ijms26041416.
5
Therapeutic Potential of Targeting the SUMO Pathway in Cancer.
Cancers (Basel). 2021 Aug 31;13(17):4402. doi: 10.3390/cancers13174402.
6
JAK/STAT pathway and molecular mechanism in bone remodeling.
Mol Biol Rep. 2020 Nov;47(11):9087-9096. doi: 10.1007/s11033-020-05910-9. Epub 2020 Oct 24.
7
A Hierarchical Machine Learning Model to Discover Gleason Grade-Specific Biomarkers in Prostate Cancer.
Diagnostics (Basel). 2019 Dec 11;9(4):219. doi: 10.3390/diagnostics9040219.
8
Targeting Oncogenic Transcription Factors: Therapeutic Implications of Endogenous STAT Inhibitors.
Trends Cancer. 2017 Dec;3(12):816-827. doi: 10.1016/j.trecan.2017.10.004. Epub 2017 Nov 10.

本文引用的文献

1
Stat5 promotes metastatic behavior of human prostate cancer cells in vitro and in vivo.
Endocr Relat Cancer. 2010 May 18;17(2):481-93. doi: 10.1677/ERC-09-0328. Print 2010 Jun.
3
Transcription factor Stat5a/b as a therapeutic target protein for prostate cancer.
Int J Biochem Cell Biol. 2010 Feb;42(2):186-92. doi: 10.1016/j.biocel.2009.11.001. Epub 2009 Nov 13.
4
Signal transducer and activator of transcription 5A/B in prostate and breast cancers.
Endocr Relat Cancer. 2008 Jun;15(2):367-90. doi: 10.1677/ERC-08-0013.
5
Stat3 promotes metastatic progression of prostate cancer.
Am J Pathol. 2008 Jun;172(6):1717-28. doi: 10.2353/ajpath.2008.071054. Epub 2008 May 15.
6
Interpretation of cytokine signaling through the transcription factors STAT5A and STAT5B.
Genes Dev. 2008 Mar 15;22(6):711-21. doi: 10.1101/gad.1643908.
8
PIAS proteins as regulators of small ubiquitin-related modifier (SUMO) modifications and transcription.
Biochem Soc Trans. 2007 Dec;35(Pt 6):1405-8. doi: 10.1042/BST0351405.
10
Purification and identification of the STAT5 protease in myeloid cells.
Biochem J. 2007 May 15;404(1):81-7. doi: 10.1042/BJ20061877.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验